A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer
|ClinicalTrials.gov Identifier: NCT00563095|
Recruitment Status : Unknown
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was: Recruiting
First Posted : November 26, 2007
Last Update Posted : July 7, 2010
Primary: To compare the efficacy of TACE and TAIE.
Secondary: To compare the side effects of TACE and TAIE.
The outcome measurements include survival benefit and tumour regression induced by the two therapies.
|Condition or disease||Intervention/treatment|
|Carcinoma, Hepatocellular||Procedure: Transcatheter Arterial Chemoembolization (TACE) Procedure: Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma|
|Study Start Date :||March 2004|
|Estimated Study Completion Date :||December 2008|
- regression of tumour size [ Time Frame: assessment every 6 months ]
- side effects [ Time Frame: every treatment given every 8 - 12 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00563095
|Contact: Man Fung Yuen, Prof||(852) 2855 firstname.lastname@example.org|
|Queen Mary Hospital||Recruiting|
|Hong Kong, China|
|Sub-Investigator: Ching Lung Lai, Prof|
|Sub-Investigator: Clara Ooi, Prof|
|Principal Investigator:||Man Fung Yuen, Prof||Department of Medicine, Queen Mary Hospital/ The University of Hong Kong|